Palvella Therapeutics (PVLA) Stock Forecast & Price Target

Compare

765 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PVLA Analyst Ratings

Strong Buy

12 Buy

0 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Palvella

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PVLA Stock 12 Month Forecast

Average Price Target

$216.62

▲(71.85% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Palvella Therapeutics in the last 3 months. The average price target is $216.62 with a high forecast of $267.00 and a low forecast of $76.43. The average price target represents a 71.85% change from the last price of $126.05.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"18":"$18","143":"$143","268":"$268","80.5":"$80.5","205.5":"$205.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":267,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$267.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":216.62,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$216.62</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":76.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$76.43</span>\n  </div></div>","useHTML":true}}],"tickPositions":[18,80.5,143,205.5,268],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,132.61,142.9476923076923,153.28538461538463,163.62307692307692,173.96076923076924,184.29846153846154,194.63615384615383,204.97384615384615,215.31153846153848,225.64923076923077,235.98692307692306,246.32461538461538,256.66230769230765,{"y":267,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,132.61,139.0723076923077,145.5346153846154,151.99692307692308,158.45923076923077,164.92153846153846,171.38384615384615,177.84615384615387,184.30846153846153,190.77076923076925,197.2330769230769,203.69538461538463,210.15769230769232,{"y":216.62,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,132.61,128.28846153846155,123.9669230769231,119.64538461538463,115.32384615384616,111.00230769230771,106.68076923076924,102.35923076923078,98.03769230769231,93.71615384615386,89.39461538461539,85.07307692307694,80.75153846153847,{"y":76.43,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.37,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.59,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.09,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.67,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.71,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.23,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.53,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.67,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.9,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.61,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$267.00

Average Price Target$216.62

Lowest Price Target$76.43

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Sam Slutsky

LifeSci Capital

$222

Buy

76.12%

Upside

Reiterated

03/16/26

Buy Rating Driven by Strong Phase 3 SELVA Data and Favorable FDA Pathway for QTORIN in Rare MLM Indication

Jeet Mukherjee

BTIG

$192→$215

Buy

70.57%

Upside

Reiterated

03/02/26

BTIG Remains a Buy on Palvella Therapeutics (PVLA)

Kaveri Pohlman

Clear Street

$200→$220

Buy

74.53%

Upside

Reiterated

03/02/26

Palvella Therapeutics (PVLA) Receives a Buy from Clear Street

Geulah Livshits

Chardan Capital

$200→$220

Buy

74.53%

Upside

Reiterated

03/01/26

Palvella Therapeutics price target raised to $220 from $200 at ChardanPalvella Therapeutics price target raised to $220 from $200 at Chardan

Danielle Brill

Truist Financial

$190→$210

Buy

66.60%

Upside

Reiterated

02/25/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Andrew Fein

H.C. Wainwright

$200→$255

Buy

102.30%

Upside

Reiterated

02/24/26

Analysts Offer Insights on Healthcare Companies: Fulcrum Therapeutics (NASDAQ: FULC) and Palvella Therapeutics (NASDAQ: PVLA)

Ritu Baral

TD Cowen

$190→$267

Buy

111.82%

Upside

Reiterated

02/24/26

Analysts Are Bullish on Top Healthcare Stocks: Amphastar Pharmaceuticals (AMPH), Palvella Therapeutics (PVLA)

Annabel Samimy

Stifel Nicolaus

$180→$250

Buy

98.33%

Upside

Reiterated

02/24/26

Analysts' Top Healthcare Picks: Protara Therapeutics (TARA), Warby Parker (WRBY)

Graig Suvannavejh

Mizuho Securities

$205→$250

Buy

98.33%

Upside

Reiterated

02/24/26

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (NASDAQ: PVLA), Larimar Therapeutics (NASDAQ: LRMR) and Cigna (NYSE: CI)

Catherine Novack

JonesTrading

$143→$209

Buy

65.81%

Upside

Reiterated

02/24/26

Palvella Therapeutics price target raised to $209 from $143 at JonesResearchPalvella Therapeutics price target raised to $209 from $143 at JonesResearch

Albert Lowe

Craig-Hallum

$175→$205

Buy

62.63%

Upside

Reiterated

02/18/26

Palvella Therapeutics (PVLA) Gets a Buy from Craig-Hallum

Whitney Ijem

Canaccord Genuity

$204→$76.43

Buy

-39.37%

Downside

Reiterated

02/05/26

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (NASDAQ: PVLA) and Progyny (NASDAQ: PGNY)

Joshua Schimmer

Cantor Fitzgerald

$200→$210

Buy

66.60%

Upside

Reiterated

12/15/25

Palvella price target raised to $210 from $200 at Cantor FitzgeraldPalvella price target raised to $210 from $200 at Cantor Fitzgerald

Trevor Allred

Oppenheimer

$120→$200

Buy

58.67%

Upside

Reiterated

12/15/25

Palvella Therapeutics price target raised to $200 from $120 at OppenheimerPalvella Therapeutics price target raised to $200 from $120 at Oppenheimer

Dev Prasad

Lucid Capital

$122→$212

Buy

68.19%

Upside

Reiterated

12/15/25

Palvella Therapeutics price target raised to $212 from $122 at Lucid CapitalPalvella Therapeutics price target raised to $212 from $122 at Lucid Capital

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Sam Slutsky

LifeSci Capital

$222

Buy

76.12%

Upside

Reiterated

03/16/26

Buy Rating Driven by Strong Phase 3 SELVA Data and Favorable FDA Pathway for QTORIN in Rare MLM Indication

Jeet Mukherjee

BTIG

$192→$215

Buy

70.57%

Upside

Reiterated

03/02/26

BTIG Remains a Buy on Palvella Therapeutics (PVLA)

Kaveri Pohlman

Clear Street

$200→$220

Buy

74.53%

Upside

Reiterated

03/02/26

Palvella Therapeutics (PVLA) Receives a Buy from Clear Street

Geulah Livshits

Chardan Capital

$200→$220

Buy

74.53%

Upside

Reiterated

03/01/26

Palvella Therapeutics price target raised to $220 from $200 at ChardanPalvella Therapeutics price target raised to $220 from $200 at Chardan

Danielle Brill

Truist Financial

$190→$210

Buy

66.60%

Upside

Reiterated

02/25/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Andrew Fein

H.C. Wainwright

$200→$255

Buy

102.30%

Upside

Reiterated

02/24/26

Analysts Offer Insights on Healthcare Companies: Fulcrum Therapeutics (NASDAQ: FULC) and Palvella Therapeutics (NASDAQ: PVLA)

Ritu Baral

TD Cowen

$190→$267

Buy

111.82%

Upside

Reiterated

02/24/26

Analysts Are Bullish on Top Healthcare Stocks: Amphastar Pharmaceuticals (AMPH), Palvella Therapeutics (PVLA)

Annabel Samimy

Stifel Nicolaus

$180→$250

Buy

98.33%

Upside

Reiterated

02/24/26

Analysts' Top Healthcare Picks: Protara Therapeutics (TARA), Warby Parker (WRBY)

Graig Suvannavejh

Mizuho Securities

$205→$250

Buy

98.33%

Upside

Reiterated

02/24/26

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (NASDAQ: PVLA), Larimar Therapeutics (NASDAQ: LRMR) and Cigna (NYSE: CI)

Catherine Novack

JonesTrading

$143→$209

Buy

65.81%

Upside

Reiterated

02/24/26

Palvella Therapeutics price target raised to $209 from $143 at JonesResearchPalvella Therapeutics price target raised to $209 from $143 at JonesResearch

Albert Lowe

Craig-Hallum

$175→$205

Buy

62.63%

Upside

Reiterated

02/18/26

Palvella Therapeutics (PVLA) Gets a Buy from Craig-Hallum

Whitney Ijem

Canaccord Genuity

$204→$76.43

Buy

-39.37%

Downside

Reiterated

02/05/26

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (NASDAQ: PVLA) and Progyny (NASDAQ: PGNY)

Joshua Schimmer

Cantor Fitzgerald

$200→$210

Buy

66.60%

Upside

Reiterated

12/15/25

Palvella price target raised to $210 from $200 at Cantor FitzgeraldPalvella price target raised to $210 from $200 at Cantor Fitzgerald

Trevor Allred

Oppenheimer

$120→$200

Buy

58.67%

Upside

Reiterated

12/15/25

Palvella Therapeutics price target raised to $200 from $120 at OppenheimerPalvella Therapeutics price target raised to $200 from $120 at Oppenheimer

Dev Prasad

Lucid Capital

$122→$212

Buy

68.19%

Upside

Reiterated

12/15/25

Palvella Therapeutics price target raised to $212 from $122 at Lucid CapitalPalvella Therapeutics price target raised to $212 from $122 at Lucid Capital

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Palvella Therapeutics

3 Months

xxx

Success Rate

10/11 ratings generated profit

Average Return

+74.17%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 90.91% of your transactions generating a profit, with an average return of +74.17% per trade.

1 Year

Andrew FeinH.C. Wainwright

Success Rate

11/11 ratings generated profit

Average Return

+323.05%

reiterated a buy rating 22 days ago

Copying Andrew Fein's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +323.05% per trade.

2 Years

xxx

Success Rate

11/11 ratings generated profit

Average Return

+355.36%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +355.36% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PVLA Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PVLA has received 33 Buy Ratings, 21 Hold Ratings, and 0 Sell Ratings. PVLA average Analyst price target in the past 3 months is 216.62.

Each month's total comprises the sum of three months' worth of ratings.

PVLA Financial Forecast

PVLA Earnings Forecast

Next quarter’s earnings estimate for PVLA is -$0.91 with a range of -$1.06 to -$0.30. The previous quarter’s EPS was -$1.03. PVLA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year PVLA has Performed in-line its overall industry.

PVLA Sales Forecast

Next quarter’s sales forecast for PVLA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. PVLA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year PVLA has Performed in-line its overall industry.

PVLA Stock Forecast FAQ

What is PVLA’s average 12-month price target, according to analysts?

Based on analyst ratings, Palvella Therapeutics’s 12-month average price target is 216.62.

What is PVLA’s upside potential, based on the analysts’ average price target?

Palvella Therapeutics has 71.85% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PVLA a Buy, Sell or Hold?

Palvella Therapeutics has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.

What is Palvella Therapeutics’s price target?

The average price target for Palvella Therapeutics is 216.62. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $267.00 ,the lowest forecast is $76.43. The average price target represents 71.85% Increase from the current price of $126.05.

What do analysts say about Palvella Therapeutics?

Palvella Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of PVLA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Palvella Therapeutics (PVLA) Stock Forecast & Price Target

PVLA Analyst Ratings

PVLA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Palvella Therapeutics

PVLA Analyst Recommendation Trends

PVLA Financial Forecast

PVLA Earnings Forecast

PVLA Sales Forecast

PVLA Stock Forecast FAQ

Detailed List of Analyst Forecasts